Department of Transplant, Mayo Clinic, Jacksonville, FL 32224, USA.
Division of Cardiovascular Imaging, University Hospital Münster, 48149, Münster, Germany.
J Comp Eff Res. 2024 Jul;13(7):e230158. doi: 10.57264/cer-2023-0158. Epub 2024 Jun 13.
The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.
六分钟步行试验（6MWT）是心力衰竭（HF）患者功能能力的常用测量方法。原发性心肌病（CM）试验的主要临床研究终点通常仅限于住院和死亡率。为了研究 6MWT 与包括转甲状腺素介导的淀粉样变性伴心肌病（ATTR-CM）在内的 CM 患者住院或死亡率之间的关系。使用 CM、6MWT、住院和死亡率的搜索词进行了 PRISMA 指导的系统文献综述。确定了 41 项研究，这些研究报告了患有 CM 的患者的 6MWT 数据和住院或死亡率数据。数据表明，6MWT 距离越大，CM 患者住院或死亡率的风险越低。6MWT 是包括 ATTR-CM 在内的 CM 试验的可接受替代终点。
